The treatment of gastric cancer (GC) has entered an era of precision medicine combining molecular subtyping, immune checkpoint inhibitors (ICIs), anti-human epidermal growth factor receptor 2 (HER2), anti-claudin 18.2 (CLDN18.2), anti-angiogenic therapy, and chemotherapy. However, efficacy remains limited by tumor micr...
Zhuoyan Wang, Yichen Du, Qinglin Gu et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.